Emerging Biological Insights and Novel Treatment Strategies in Primary Mediastinal Large B-Cell Lymphoma

Seminars in Hematology

Volumn 52, Issue 2, 2015, Pages 119-125

  Dunleavy, Kieron ^a   Steidl, Christian ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRENTUXIMAB VEDOTIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; JANUS KINASE; JANUS KINASE 2; PREDNISONE; PROGRAMMED DEATH 1 RECEPTOR; STAT PROTEIN; STAT6 PROTEIN; VINCRISTINE;

ADAPTIVE IMMUNITY; CANCER CHEMOTHERAPY; DRUG EFFICACY; GENE AMPLIFICATION; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MEDIASTINAL GREY ZONE LYMPHOMA; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT PLANNING; GENETICS; IMMUNOTHERAPY; LYMPHOMA, B-CELL; MEDIASTINUM TUMOR; METABOLISM;

HUMANS; IMMUNOTHERAPY; JANUS KINASES; LYMPHOMA, B-CELL; MEDIASTINAL NEOPLASMS; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 84925259944     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2015.01.002     Document Type: Review

References (48)

1. Rosenwald A., Wright G., Leroy K., et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003, 198(6):851-862.
2. Gunawardana J., Chan F.C., Telenius A., et al. Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma. Nat Genet 2014, 46(4):329-335.
3. Eberle F.C., Salaverria I., Steidl C., et al. Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations. Mod Pathol 2011, 24(12):1586-1597.
4. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, IARC, Lyon, France. S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
5. Grant C., Dunleavy K., Eberle F.C., Pittaluga S., Wilson W.H., Jaffe E.S. Primary mediastinal large B-cell lymphoma, classic Hodgkin lymphoma presenting in the mediastinum, and mediastinal gray zone lymphoma: what is the oncologist to do?. Curr Hematol Malig Rep 2011, 6(3):157-163.
6. Steidl C., Gascoyne R.D. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood 2011, 118(10):2659-2669.
7. Twa D.D.W., Chan F.C., Ben-Neriah S., et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood 2014, 123(13):2062-2065.
8. Wessendorf S., Barth T.F., Viardot A., et al. Further delineation of chromosomal consensus regions in primary mediastinal B-cell lymphomas: an analysis of 37 tumor samples using high-resolution genomic profiling (array-CGH). Leukemia 2007, 21(12):2463-2469.
9. Darnell J.E., Kerr I.M., Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264(5164):1415-1421.
10. Guiter C., Dusanter-Fourt I., Copie-Bergman C., et al. Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. Blood 2004, 104(2):543-549.
11. Raia V., Schilling M., Bohm M., et al. Dynamic mathematical modeling of IL13-induced signaling in Hodgkin and primary mediastinal B-cell lymphoma allows prediction of therapeutic targets. Cancer Res 2011, 71(3):693-704.
12. Andersson E., Schain F., Sjoberg J., Bjorkholm M., Claesson H.E. Interleukin-13 stimulation of the mediastinal B-cell lymphoma cell line Karpas-1106P induces a phenotype resembling the Hodgkin lymphoma cell line L1236. Exp Hematol 2010, 38(2):116-123.
13. Joos S., Otano-Joos M.I., Ziegler S., et al. Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood 1996, 87(4):1571-1578.
14. Rui L., Emre N.C., Kruhlak M.J., et al. Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell 2010, 18(6):590-605.
15. Melzner I., Bucur A.J., Bruderlein S., et al. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood 2005, 105(6):2535-2542.
16. Mottok A., Renne C., Willenbrock K., Hansmann M.L., Brauninger A. Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6. Blood 2007, 110(9):3387-3390.
17. Weniger M.A., Melzner I., Menz C.K., et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene 2006, 25(18):2679-2684.
18. Lu X., Malumbres R. Shields Bet al. PTP1B is a negative regulator of interleukin 4-induced STAT6 signaling. Blood 2008, 112(10):4098-4108.
19. Ritz O., Guiter C., Castellano F., et al. Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma. Blood 2009, 114(6):1236-1242.
20. Scott D.W., Gascoyne R.D. The tumour microenvironment in B cell lymphomas. Nat Rev Cancer 2014, 14(8):517-534.
21. Rigaud G., Moore P.S., Taruscio D., et al. Alteration of chromosome arm 6p is characteristic of primary mediastinal B-cell lymphoma, as identified by genome-wide allelotyping. Genes Chromosomes Cancer 2001, 31(2):191-195.
22. Roberts R.A., Wright G., Rosenwald A.R., et al. Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival. Blood 2006, 108(1):311-318.
23. Steidl C., Shah S.P., Woolcock B.W., et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 2011, 471(7338):377-381.
24. Savage K.J., Monti S., Kutok J.L., et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003, 102(12):3871-3879.
25. Green M.R., Monti S., Rodig S.J., et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010, 116(17):3268-3277.
26. Zinzani P.L., Martelli M., Bertini M., et al. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica 2002, 87(12):1258-1264.
27. Martelli M., Ceriani L., Zucca E., et al. [18F]Fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. Blood 2014, 124(10):1563-1569.
28. Castellino S.M., Geiger A.M., Mertens A.C., et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood 2011, 117(6):1806-1816.
29. O'Brien M.M., Donaldson S.S., Balise R.R., Whittemore A.S., Link M.P. Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy. J Clin Oncol 2010, 28(7):1232-1239.
30. Rieger M., Osterborg A., Pettengell R., et al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol 2011, 22(3):664-670.
31. Soumerai J.D., Hellmann M.D., Feng Y., et al. Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease. Leuk Lymphoma 2014, 55(3):538-543.
32. Savage K.J., Al-Rajhi N., Voss N., et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol 2006, 17(1):123-130.
33. Savage K.J., Yenson P.R., Shenkier T., et al. The outcome of primary mediastinal large B-cell lymphoma (PMBCL) in the R-CHOP treatment era. Blood (ASH Annual Meeting Abstracts) 2012, 120. [Abstract 303].
34. Dunleavy K., Pittaluga S., Maeda L.S., et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 2013, 368(15):1408-1416.
35. Woessmann W., Lisfeld J., Burkhardt B. Therapy in primary mediastinal B-cell lymphoma. N Engl J Med 2013, 369(3):282.
36. Cazals-Hatem D., Andre M., Mounier N., et al. Pathologic and clinical features of 77 Hodgkin's lymphoma patients treated in a lymphoma protocol (LNH87): a GELA study. Am J Surg Pathol 2001, 25(3):297-306.
37. Dunleavy K., Grant C., Eberle F.C., Pittaluga S., Jaffe E.S., Wilson W.H. Gray zone lymphoma: better treated like hodgkin lymphoma or mediastinal large B-cell lymphoma?. Current hematologic malignancy reports 2012, 7(3):241-247.
38. Wilson W.H., Pittaluga S., Nicolae A., et al. A prospective study of mediastinal gray zone lymphoma. Blood 2014.
39. Provencio M., Sanchez A., Sanchez-Beato M. New drugs and targeted treatments in Hodgkin's lymphoma. Cancer Treat Rev 2014, 40(3):457-464.
40. de Claro R.A., McGinn K., Kwitkowski V., et al. U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res 2012, 18(21):5845-5849.
41. Monjanel H., Deville L., Ram-Wolff C., et al. Brentuximab vedotin in heavily treated Hodgkin and anaplastic large-cell lymphoma, a single centre study on 45 patients. Br J Haematol 2014, 166(2):306-308.
42. Naidoo J., Page D.B., Wolchok J.D. Immune modulation for cancer therapy. Br J Cancer 2014, 111(12):2214-2219.
43. Bryan L.J., Gordon L.I. Blocking tumor escape in hematologic malignancies: the anti-PD-1 strategy. Blood Rev 2015, 29(1):25-32.
44. Armand P., Nagler A., Weller E.A., et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol 2013, 31(33):4199-4206.
45. Ansell S.M., Lesokhin A.M., Borrello I., et al. PD-1 Blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015, 372(4):311-319.
46. Hao Y., Chapuy B., Monti S., Sun H.H., Rodig S.J., Shipp M.A. Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo. Clin Cancer Res 2014, 20(10):2674-2683.
47. Younes A., Romaguera J., Fanale M., et al. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin Oncol 2012, 30(33):4161-4167.
48. Kochenderfer J.N., Dudley M.E., Kassim S.H., et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015, 33(6):540-549.